Meeting
2018 ASCO Annual Meeting
Ipilimumab and radiation in patients with unresectable melanoma brain metastases: A multicenter, open label, phase-2, Spanish Melanoma Group (GEM) study (NCT-2013-001132-22).
Authors
Jose A. Lopez-Martin
Medical Oncology Department, Hospital 12 de Octubre, Madrid, Spain
Jose A. Lopez-Martin , Ana M. Arance , Luis De La Cruz-Merino , Ana Illescas , Izazkun Valduvieco , Alfonso Berrocal , José López Torrecilla , Ivan Marquez Rodas , Maria Teresa Curiel Garcia , Virtudes Soriano , Ana Alvarez , M.L. Chust Vicente , Delvys Rodriguez-Abreu , M.C. Peñas Sanchez , Eva Muñoz-Couselo , Javier Aristu , Antonio Gomez Caamaño , Salvador Martin-Algarra
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
2013-001132- 22
Citation
J Clin Oncol 36, 2018 (suppl; abstr 9546)
DOI
10.1200/JCO.2018.36.15_suppl.9546
Abstract #
9546
Poster Bd #
373
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Vemurafenib (VEM) in patients (pts) with BRAF-mutant melanoma and brain metastases (mets).
First Author: James J. Harding
Poster
2021 ASCO Annual Meeting
Two dosing regimens of nivolumab (NIVO) plus ipilimumab (IPI) for advanced (adv) melanoma: Three-year results of CheckMate 511.
First Author: Celeste Lebbe
Poster
2017 ASCO Annual Meeting
Role of time to switch from ipilimumab to anti-PD1 in anti-PD1 efficacy within the French national cohort, MelBase.
First Author: Clara Allayous
Poster
2016 ASCO Annual Meeting
Immunotherapy-treated melanoma brain metastases within the French national cohort, MelBase.
First Author: Clara Allayous